[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100055142":3},{"organization":4,"armGroups":7,"interventions":8,"overallOfficials":7,"centralContacts":7,"locations":18,"responsibleParty":7,"collaborators":72,"id":78,"slug":79,"hasResults":80,"nctId":81,"briefTitle":82,"officialTitle":83,"acronym":7,"eligibilityCriteria":84,"healthyVolunteers":80,"sex":85,"minAge":86,"maxAge":7,"enrollmentInfo":87,"targetDuration":7,"studyType":89,"phases":90,"briefSummary":92,"conditions":93,"keywords":95,"overallStatus":99,"whyStopped":7,"lastUpdateSubmitDate":100,"lastUpdatePostDateStruct":101,"startDateStruct":7,"completionDateStruct":7,"leadSponsor":104,"locationsCount":106},{"fullName":5,"class":6},"Bristol-Myers Squibb","INDUSTRY",null,[9,12,14,16],{"type":10,"name":11,"description":7,"armGroupLabels":7,"otherNames":7},"DRUG","Efavirenz",{"type":10,"name":13,"description":7,"armGroupLabels":7,"otherNames":7},"Adefovir dipivoxil",{"type":10,"name":15,"description":7,"armGroupLabels":7,"otherNames":7},"Lamivudine",{"type":10,"name":17,"description":7,"armGroupLabels":7,"otherNames":7},"Didanosine",[19,32,42,52,62],{"facility":20,"status":7,"city":21,"state":22,"zip":23,"country":24,"countryCode":25,"cosmosGeoPoint":26,"geoPoint":31,"contacts":7},"Pacific Oaks Med Group","Beverly Hills","California","90211","United States","US",{"type":27,"coordinates":28},"Point",[29,30],-118.40036,34.07362,{"lat":30,"lon":29},{"facility":33,"status":7,"city":34,"state":35,"zip":36,"country":24,"countryCode":25,"cosmosGeoPoint":37,"geoPoint":41,"contacts":7},"Univ of Colorado \u002F Health Science Ctr","Denver","Colorado","80262",{"type":27,"coordinates":38},[39,40],-104.9847,39.73915,{"lat":40,"lon":39},{"facility":43,"status":7,"city":44,"state":45,"zip":46,"country":24,"countryCode":25,"cosmosGeoPoint":47,"geoPoint":51,"contacts":7},"AIDS Research Consortium of Atlanta","Atlanta","Georgia","30308",{"type":27,"coordinates":48},[49,50],-84.38798,33.749,{"lat":50,"lon":49},{"facility":53,"status":7,"city":54,"state":55,"zip":56,"country":24,"countryCode":25,"cosmosGeoPoint":57,"geoPoint":61,"contacts":7},"Brown Univ School of Medicine","Providence","Rhode Island","02908",{"type":27,"coordinates":58},[59,60],-71.41283,41.82399,{"lat":60,"lon":59},{"facility":63,"status":7,"city":64,"state":65,"zip":66,"country":24,"countryCode":25,"cosmosGeoPoint":67,"geoPoint":71,"contacts":7},"Hampton Roads Med Specialists","Hampton","Virginia","23666",{"type":27,"coordinates":68},[69,70],-76.34522,37.02987,{"lat":70,"lon":69},[73,74,76],{"name":5,"class":6},{"name":75,"class":6},"Glaxo Wellcome",{"name":77,"class":6},"Dupont Applied Biosciences","100055142","phase-2-safety-and-effectiveness-of-giving-an-anti-hiv-drug-combination-of-adefovir-dipivoxil-plus-didanosine-plus-efavirenz-plus-lamivudine-once-daily-to-hiv-infected-patients-100055142",false,"NCT00002234","Safety and Effectiveness of Giving an Anti-HIV Drug Combination of Adefovir Dipivoxil Plus Didanosine Plus Efavirenz Plus Lamivudine Once Daily to HIV-Infected Patients","A Phase II, 48 Week, Open-Label Study Designed to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of a Simplified Dosing Regimen of Preveon (Adefovir Dipivoxil; bis-POM PMEA), Videx (Didanosine; ddI), Sustiva (Efavirenz; DMP-266), and Epivir (Lamivudine; 3TC) Administered Once Daily for the Treatment of HIV-1 Infection","Inclusion Criteria\n\nYou may be eligible for this study if you:\n\n* Are HIV-positive.\n* Are at least 13 years old (need consent of parent or guardian if under 18).\n* Have an HIV count of 5,000 copies\u002Fml or more within 30 days prior to study entry.\n* Have a CD4+ count of 50 cells\u002Fmm3 or more.\n\nExclusion Criteria\n\nYou will not be eligible for this study if you:\n\n* Are diagnosed with hepatitis within 30 days prior to study entry.\n* Have certain serious medical conditions, including an AIDS-defining clinical condition.\n* Received chemotherapy or radiation therapy within 30 days of study entry.\n* Have taken any nucleoside reverse transcriptase inhibitors (NRTIs) for more than 2 weeks.\n* Have ever taken 3TC.\n* Have ever taken any non-nucleoside reverse transcriptase inhibitors (NNRTIs).\n* Have taken medications that affect your immune system within 30 days prior to study entry.\n* Have received a vaccine within 30 days prior to study entry.\n* Are enrolled in another anti-HIV drug study while participating in this study.\n* Abuse alcohol or drugs.\n* Are pregnant or breast-feeding.","ALL","13 Years",{"count":88,"type":7},25,"INTERVENTIONAL",[91],"PHASE2","The purpose of this study is to see if it is safe and effective to give HIV-infected patients a new combination of anti-HIV drugs taken once daily.",[94],"HIV Infections",[96,97,98],"Drug Therapy, Combination","Reverse Transcriptase Inhibitors","Anti-HIV Agents","COMPLETED","2005-06-23",{"date":102,"type":103},"2005-06-24","ESTIMATED",{"name":105,"class":6},"Gilead Sciences",5]